Isomorphic Labs has secured $5 billion in Series C funding, co-led by Greenoaks and Sequoia Capital, with continued investment from Alphabet and other existing backers. This latest round follows previous significant funding, including a $600 million round in March 2025 and a $2.1 billion Series B in May 2026. Despite these substantial investments, the AI drug discovery company, founded by Demis Hassabis, has yet to announce any drug candidates entering human trials, though it reports positive preclinical results in oncology and immunology programs. AI
IMPACT This substantial funding could accelerate AI-driven drug discovery, potentially leading to faster development of new therapeutics.
RANK_REASON Significant funding round for an AI-focused company. [lever_c_demoted from significant: ic=1 ai=0.7]
- Alphabet
- CapitalG
- Demis Hassabis
- Greenoaks
- GV
- Isomorphic Labs
- Sequoia Capital
- Temasek
- Thrive Capital
- UK Sovereign AI Fund
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →